Dexamethasone, Flurbiprofen Axetil and Long-term Survival After Lung Cancer Surgery
Status:
Terminated
Trial end date:
2018-12-26
Target enrollment:
Participant gender:
Summary
Surgical resection is the first choice treatment for patients with non-small-cell lung
cancer. Despite of advances in surgical techniques, the long-term survival rate of
postoperative patient is far from optimal. In a recent retrospective cohort study of the
applicants, 588 patients after surgery for non-small-cell lung cancer were followed up for a
medium of 5.2 years. The results showed that perioperative use of dexamethasone was
associated with prolonged survival; perioperative use of flurbiprofen axetil was also
associated with a slightly longer survival but not statistically significant. Further
analysis showed that combined administration of dexamethasone and flurbiprofen axetil had
additive effect in prolonging survival. We hypothesize that, for patients undergoing surgery
for non-small-cell lung cancer, perioperative administration of dexamethasone and
flurbiprofen axetil may improve long-term survival. However, evidences from randomized
controlled trials are still lacking in this aspect.